Johnson & Johnson
JNJ
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $645.9B
$265.85
▼ -0.82%
P/E
30.81
Mkt Cap
$645.9B
52-Wk Range
$173.33–$276.47
52-Week Range
$173.33 - $276.47
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 50.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Diversified portfolio across pharmaceuticals and medical devices reduces revenue concentration risk
- Strong R&D pipeline with focus on high-growth therapeutic areas and innovative treatment modalities
- Established global distribution network and brand recognition built over 135+ years
- Significant intellectual property portfolio and patent protections providing pricing power
- Scale advantages in manufacturing, regulatory expertise, and clinical trial capabilities
Bear Case
2 risks
- Low volatility (beta 0.2).
- High premium - requires strong execution
Growth
Stable outlook
Aging global population driving demand for innovative medicines and medical devices
Value
High premium - requires strong execution
Momentum
Strong
+18.9% over 3m
Quality
Excellent
Excellent business quality
Dividend
Modest
1.97% yield
Smart-money signal
Who's buying JNJ right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 13, 2026
JUL 15, 2026
Reported EPS of $2.90 vs $2.84 consensus (+2.1% surprise). Revenue of $25.3B vs $25.1B expected (+1.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2.1%
Revenue trend · last 8Q
—
+5%
+2%
+6%
+7%
+9%
+10%
+7%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$22.5B
$22.5B
$21.9B
$23.7B
$24.0B
$24.6B
$24.1B
$25.3B
Margins · last 8Q
Gross
73.1%
Operating
28.3%
Profit
21.9%
Wall Street consensus
15 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 6, 2026
vs Industry
How JNJ stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related